<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00064233</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000310142</org_study_id>
    <secondary_id>UCLA-0303035</secondary_id>
    <secondary_id>BMS-CA180002</secondary_id>
    <nct_id>NCT00064233</nct_id>
  </id_info>
  <brief_title>BMS-354825 in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Is Resistant to Imatinib Mesylate</brief_title>
  <official_title>A Phase I Dose-Escalation Study To Determine The Safety, Pharmacokinetics, And Pharmacodynamics Of BMS-354825 In The Treatment Of Patients With Chronic Phase Chronic Myelogenous Leukemia Who Have Hematologic Resistance To Imatinib Mesylate (Gleevec</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: BMS-354825 may stop the growth of cancer cells by stopping the enzymes necessary&#xD;
      for cancer cell growth.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of BMS-354825 in&#xD;
      treating patients with chronic phase chronic myelogenous leukemia that is resistant to&#xD;
      imatinib mesylate.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose, maximum administered dose, dose-limiting toxicity,&#xD;
           and a recommended phase II dose of BMS-354825 in patients with chronic phase chronic&#xD;
           myelogenous leukemia who have hematologic resistance to imatinib mesylate.&#xD;
&#xD;
        -  Determine the safety and tolerability of this drug in these patients.&#xD;
&#xD;
        -  Determine the plasma pharmacokinetics of this drug in these patients.&#xD;
&#xD;
        -  Determine, preliminarily, the efficacy of this drug, in terms of hematologic,&#xD;
           cytogenetic, and molecular responses in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, dose-escalation, multicenter study.&#xD;
&#xD;
      Patients receive oral BMS-354825 once daily on days 1-5. Courses repeat every 7 days for at&#xD;
      least 3 months in the absence of disease progression or unacceptable toxicity. Patients may&#xD;
      receive further treatment in the absence of disease progression.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of BMS-354825 until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6&#xD;
      patients experience dose-limiting toxicity.&#xD;
&#xD;
      Once the MTD is determined, 20 additional patients receive treatment as in phase I at the MTD&#xD;
      of BMS-354825.&#xD;
&#xD;
      Patients are followed for at least 30 days.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 50 patients (30 for phase I and 20 for phase II) will be&#xD;
      accrued for this study within 12-18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">42</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dasatinib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          -  Diagnosis of Philadelphia chromosome positive, chronic phase chronic myelogenous&#xD;
             leukemia (CML) meeting all of the following criteria*:&#xD;
&#xD;
          -  Less than 15% blasts in peripheral blood and bone marrow&#xD;
&#xD;
          -  Less than 20% basophils in peripheral blood&#xD;
&#xD;
          -  Less than 30% blasts and promyelocytes in peripheral blood and bone marrow&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3 NOTE: *Patients who previously met the criteria&#xD;
             for accelerated phase or blast phase CML, responded to treatment, and currently meet&#xD;
             the criteria for chronic phase CML are eligible&#xD;
&#xD;
          -  Primary or acquired hematologic resistance to imatinib mesylate OR intolerance to&#xD;
             imatinib mesylate defined as follows:&#xD;
&#xD;
          -  Primary hematologic resistance is defined as failure to reach complete hematologic&#xD;
             response (CHR) with a dose of 400 mg/day continued for at least 3 months&#xD;
&#xD;
               -  Patients with hematological progression (i.e., WBC at least 10,000/mm^3 and&#xD;
                  rising consistently on at least 2 consecutive measurements obtained at least 14&#xD;
                  days apart) while receiving imatinib mesylate of 400 mg/day are eligible if they&#xD;
                  have received less than 3 months of therapy&#xD;
&#xD;
          -  Acquired hematologic resistance is defined as achieving a CHR, but subsequently&#xD;
             developing a rising WBC to at least 10,000/mm^3&#xD;
&#xD;
               -  WBC must be at least 10,000/mm^3 and rising on at least 2 measurements obtained&#xD;
                  at least 14 days apart with at least 1 of these measurements greater than&#xD;
                  15,000/mm^3&#xD;
&#xD;
          -  Intolerance is defined as having discontinued imatinib mesylate due to nonhematologic&#xD;
             toxicity of any grade&#xD;
&#xD;
               -  CD4^+ T-cell count at least 350/mm^3&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
          -  Life expectancy, At least 6 months.&#xD;
&#xD;
          -  Hepatic&#xD;
&#xD;
               -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
               -  ALT and AST no greater than 2.0 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Renal&#xD;
&#xD;
               -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
               -  Potassium normal*&#xD;
&#xD;
               -  Magnesium normal*&#xD;
&#xD;
               -  Serum calcium or ionized calcium at least lower limit of normal NOTE: *Patients&#xD;
                  with low levels may be repleted to be eligible&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception for 1 month before, during, and 1&#xD;
             month after study participation&#xD;
&#xD;
          -  More than 14 days since prior interferon&#xD;
&#xD;
          -  More than 14 days since prior cytarabine&#xD;
&#xD;
          -  More than 3 days since prior hydroxyurea&#xD;
&#xD;
          -  More than 28 days since other prior investigational or antineoplastic agents&#xD;
&#xD;
          -  More than 7 days since prior imatinib mesylate&#xD;
&#xD;
          -  At least 5 days or 5 half-lives since prior medications that inhibit platelet&#xD;
             function, including the following:&#xD;
&#xD;
          -  Aspirin&#xD;
&#xD;
          -  Dipyridamole&#xD;
&#xD;
          -  Epoprostenol&#xD;
&#xD;
          -  Eptifibatide&#xD;
&#xD;
          -  Clopidogrel&#xD;
&#xD;
          -  Cilostazol&#xD;
&#xD;
          -  Abciximab&#xD;
&#xD;
          -  Ticlopidine&#xD;
&#xD;
          -  At least 5 days or 5 half-lives since prior anticoagulants such as warfarin or&#xD;
             heparin/low molecular weight heparin (e.g., danaparoid, dalteparin, tinzaparin,&#xD;
             enoxaparin)&#xD;
&#xD;
          -  At least 5 days or 5 half-lives since prior drugs accepted to have a risk of causing&#xD;
             torsades de pointes, including the following:&#xD;
&#xD;
          -  Class IA antiarrhythmic agents (e.g., quinidine, procainamide, or disopyramide)&#xD;
&#xD;
          -  Class III antiarrhythmic agents (e.g., amiodarone, sotalol, ibutilide, or dofetilide)&#xD;
&#xD;
          -  Macrolide antibiotics (e.g., erythromycin or clarithromycin)&#xD;
&#xD;
          -  Antipsychotics (e.g., chlorpromazine, haloperidol, thioridazine, or pimozide)&#xD;
&#xD;
          -  Tricyclic antidepressants&#xD;
&#xD;
          -  Cisapride&#xD;
&#xD;
          -  Bepridil&#xD;
&#xD;
          -  Inapsine&#xD;
&#xD;
          -  Methadone&#xD;
&#xD;
          -  Arsenic&#xD;
&#xD;
          -  Concurrent anagrelide for thrombocytosis due to CML allowed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  extramedullary involvement (other than liver or spleen)&#xD;
&#xD;
          -  significant bleeding disorder unrelated to CML&#xD;
&#xD;
          -  acquired bleeding disorder within the past year (e.g., acquired antifactor VIII&#xD;
             antibodies)&#xD;
&#xD;
          -  congenital bleeding disorders (e.g., von Willebrand disease)&#xD;
&#xD;
          -  uncontrolled or significant cardiovascular disease&#xD;
&#xD;
          -  uncontrolled angina within the past 6 months&#xD;
&#xD;
          -  congestive heart failure within the past 6 months&#xD;
&#xD;
          -  myocardial infarction within the past 12 months&#xD;
&#xD;
          -  history of clinically significant ventricular arrhythmias (e.g., ventricular&#xD;
             tachycardia, ventricular fibrillation, or torsades de pointes)&#xD;
&#xD;
          -  history of second or third degree heart block (may be eligible if patient has a&#xD;
             pacemaker)&#xD;
&#xD;
          -  diagnosed or suspected congenital long QT syndrome&#xD;
&#xD;
          -  prolonged QTc interval on pre-entry EKG (i.e., greater than 450 msec)&#xD;
&#xD;
          -  heart rate less than 50/minute on pre-entry EKG&#xD;
&#xD;
          -  uncontrolled hypertension&#xD;
&#xD;
          -  vasculitis&#xD;
&#xD;
          -  pregnant or nursing&#xD;
&#xD;
          -  gastrointestinal tract bleeding within the past 6 months&#xD;
&#xD;
          -  connective tissue disorders&#xD;
&#xD;
          -  other serious uncontrolled medical disorder or active infection that would impair the&#xD;
             ability to receive study therapy&#xD;
&#xD;
          -  dementia or altered mental status that would preclude giving informed consent&#xD;
&#xD;
          -  evidence of organ dysfunction or any clinically significant deviation from normal in&#xD;
             physical examination, vital signs, EKG, or clinical laboratory determinations&#xD;
             unrelated to CML&#xD;
&#xD;
          -  prisoners or patients who are compulsorily detained (e.g., involuntary incarceration&#xD;
             for treatment of either a psychiatric or physical [e.g., infectious disease] illness)&#xD;
&#xD;
          -  concurrent drugs accepted to have a risk of causing torsades de pointes&#xD;
&#xD;
          -  other concurrent treatment for CML&#xD;
&#xD;
          -  concurrent dolasetron or droperidol&#xD;
&#xD;
          -  concurrent anticoagulants&#xD;
&#xD;
          -  concurrent medications that inhibit platelet function&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Sawyers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Cortes J, Sawyers CL, Kantarjian HM, et al.: Long-term efficacy of dasatinib in chronic-phase CML: results from the phase I trial (CA180002). [Abstract] Blood 110 (11): A-1026, 2007.</citation>
  </results_reference>
  <results_reference>
    <citation>Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006 Jun 15;354(24):2531-41.</citation>
    <PMID>16775234</PMID>
  </results_reference>
  <results_reference>
    <citation>Talpaz M, Kantarjian HM, Paquette R, et al.: A phase I study of BMS-354825 in patients with imatinib-resistant and intolerant chronic phase chronic myeloid leukemia (CML): results from CA180002. [Abstract] J Clin Oncol 23 (Suppl 16): A-6519, 564s, 2005.</citation>
  </results_reference>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>July 8, 2003</study_first_submitted>
  <study_first_submitted_qc>July 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2003</study_first_posted>
  <last_update_submitted>July 30, 2020</last_update_submitted>
  <last_update_submitted_qc>July 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>Philadelphia chromosome positive chronic myelogenous leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

